Cytophage Develops Freeze-Dried Phage Tablets For Poultry

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

Cytophage Technologies (TSXV: CYTO) has announced the launch of a simplified application option for its bacteriophages that it believes will set itself apart within the phage industry globally.

The company has developed a lyophilized phage tablet intended to treat multiple types of bacteria, including E. coli and Salmonella, throughout the lifecycle of poultry. The use of lyophilized phage tablets is providing an alternative to the liquid form that is presently used in the industry, which most often requires a cold chain.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life,” commented Dr Steven Theriault.

READ: Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

The tablets are freeze dried and stabilized, which enable Cytophage’s phage products to be more easily used in hot climates such as Southeast Asia. The tablets are ready to use, dose controlled, and dissolve in water for application.

Development of the tablet is said to be a direct response to Cytophage working with the poultry industry on phage products that assist in reducing the use of broad-spectrum antibiotics, and replacing those antibiotics with target phages. The firm intends to leverage the new product format across its existing and pending product lines globally.

Cytophage Technologies last traded at $0.35 on the TSX Venture.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

Golden Cariboo’s First Quesnelle Resource Estimate Tallies 1.19 Million Gold Equivalent Ounces

Brixton Wraps Camp Creek Drilling With 17.58 Metres of 1.47 g/t Gold Equivalent

Related News

Cytophage Launches Trials For OvaPhage Under Hatchery Partnership

Cytophage Technologies (TSXV: CYTO) has officially launched trials with one of the largest poultry hatcheries...
Thursday, February 6, 2025, 07:29:00 AM

Cytophage Sees Its Bacteriophages Used As Treatment In Canada Under Single Subject Clinical Trial

For the first time in Canadian history, bacteriophage therapy is slated to be utilized to...
Friday, March 1, 2024, 10:14:56 AM

Cytophage Reports Early Success In Single Subject Clinical Trial

Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted...
Tuesday, April 2, 2024, 09:05:42 AM

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy...
Thursday, August 15, 2024, 02:04:00 PM

The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies. In this interview, Dr. Steven Theriault...

Thursday, February 22, 2024, 01:30:00 PM